Baseline characteristics of patients receiving CD34+ selected SCB
| Total . | N . | % . |
|---|---|---|
| Patients | 58 | 100 |
| Recipient age at HCT, median (range) | 62 (18-76) | |
| Donor age at HCT, median (range), y | 34 (16-65) | |
| Donor type, n (%) | ||
| MRD | 9 | 16 |
| MUD | 22 | 38 |
| MMUD | 9 | 16 |
| Haplo | 18 | 31 |
| Disease at HCT, n (%) | ||
| AML/ALL | 23 | 40 |
| MDS/MPN | 20 | 34 |
| Other | 15 | 26 |
| Cell source at HCT, n (%) | ||
| BM | 16 | 28 |
| PBSC | 42 | 62 |
| PGF at boost, n (%) | ||
| Yes | 32 | 55 |
| No | 26 | 45 |
| Time from engraftment to boost, median (range), d | 164 (19-1728) | |
| CD34 per kg at boost, median (range) | 3.88 (0.99-9.92) | |
| CD34 product at boost, n (%) | ||
| Fresh | 50 | 86 |
| Cryopreserved | 6 | 10 |
| Data not available | 2 | 4 |
| Infection at boost, n (%) | ||
| Any | 15 | 26 |
| Fungal | 9 | 16 |
| Bacterial | 10 | 17 |
| Viral | 3 | 5 |
| Myelosuppressive medications∗ at boost, n (%) | ||
| Yes | 24 | 41 |
| No | 34 | 59 |
| Active disease at boost† , n (%) | ||
| Yes | 10 | 17 |
| No | 48 | 83 |
| Myeloid chimerism at SCB, n (%) | ||
| ≥90% | 48 | 83 |
| <90% | 8 | 14 |
| NA | 2 | 3 |
| T-cell chimerism at SCB, n (%) | ||
| ≥90% | 31 | 53 |
| <90% | 11 | 19 |
| NA | 16 | 28 |
| BM fibrosis at boost, n (%) | ||
| Yes | 9 | 16 |
| No | 40 | 68 |
| NA | 9 | 16 |
| BM hemosiderin at boost, n (%) | ||
| Yes | 31 | 53 |
| No | 19 | 33 |
| NA | 8 | 14 |
| Total . | N . | % . |
|---|---|---|
| Patients | 58 | 100 |
| Recipient age at HCT, median (range) | 62 (18-76) | |
| Donor age at HCT, median (range), y | 34 (16-65) | |
| Donor type, n (%) | ||
| MRD | 9 | 16 |
| MUD | 22 | 38 |
| MMUD | 9 | 16 |
| Haplo | 18 | 31 |
| Disease at HCT, n (%) | ||
| AML/ALL | 23 | 40 |
| MDS/MPN | 20 | 34 |
| Other | 15 | 26 |
| Cell source at HCT, n (%) | ||
| BM | 16 | 28 |
| PBSC | 42 | 62 |
| PGF at boost, n (%) | ||
| Yes | 32 | 55 |
| No | 26 | 45 |
| Time from engraftment to boost, median (range), d | 164 (19-1728) | |
| CD34 per kg at boost, median (range) | 3.88 (0.99-9.92) | |
| CD34 product at boost, n (%) | ||
| Fresh | 50 | 86 |
| Cryopreserved | 6 | 10 |
| Data not available | 2 | 4 |
| Infection at boost, n (%) | ||
| Any | 15 | 26 |
| Fungal | 9 | 16 |
| Bacterial | 10 | 17 |
| Viral | 3 | 5 |
| Myelosuppressive medications∗ at boost, n (%) | ||
| Yes | 24 | 41 |
| No | 34 | 59 |
| Active disease at boost† , n (%) | ||
| Yes | 10 | 17 |
| No | 48 | 83 |
| Myeloid chimerism at SCB, n (%) | ||
| ≥90% | 48 | 83 |
| <90% | 8 | 14 |
| NA | 2 | 3 |
| T-cell chimerism at SCB, n (%) | ||
| ≥90% | 31 | 53 |
| <90% | 11 | 19 |
| NA | 16 | 28 |
| BM fibrosis at boost, n (%) | ||
| Yes | 9 | 16 |
| No | 40 | 68 |
| NA | 9 | 16 |
| BM hemosiderin at boost, n (%) | ||
| Yes | 31 | 53 |
| No | 19 | 33 |
| NA | 8 | 14 |
Other includes patients with non-Hodgkin lymphoma, BM failure, chronic lymphocytic leukemia, and T-cell prolymphocytic leukemia. AML/ALL, acute myeloid leukemia or acute lymphoblastic leukemia; Haplo, haploidentical; MDS/MPN, myelodysplastic syndrome and/or myeloproliferative neoplasm; MMUD, single-antigen mismatched unrelated donor; MRD, HLA-matched related donor; MUD, HLA-matched unrelated donor; NA, not available; PBSC, peripheral blood stem cell.
Myelosuppressive medications include sirolimus, valganciclovir, ruxolitinib, cellcept, and tyrosine kinase inhibitor.
Refers to patients who had measurable residual disease in the BM or else were receiving therapy for relapse immediately before receiving CD34-selected SCB.